Gene Therapy for Corneal Diseases.
- 1Department of Ophthalmology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
Abstract
Corneal diseases are a major cause of blindness and visual impairment worldwide. Although conventional pharmacological therapies can alleviate mild to moderate corneal disorders, they often fail to restore vision in advanced disease, leaving corneal transplantation as the current standard treatment. However, donor tissue shortages, graft rejection, and surgical complications continue to limit its long-term success, highlighting the urgent need for effective nonsurgical therapeutic strategies. Gene therapy has emerged as a promising approach for treating inherited and acquired corneal diseases by targeting the underlying molecular mechanisms that drive disease progression. Recent advances in genome-editing technologies, gene-delivery systems, and vector engineering have substantially expanded the clinical potential of gene-based interventions. This review summarizes current progress in gene-editing strategies, gene-delivery platforms, and their therapeutic applications across a broad spectrum of corneal diseases. In addition, we discuss the major challenges and future perspectives associated with delivery efficiency, safety, vector optimization, and clinical translation. Collectively, these advances highlight the potential of gene therapy to transform the management of corneal diseases by providing safe, targeted, and long-lasting therapeutic strategies for restoring corneal function and vision.
Related
- Should ApoE4 gene editing therapy be approached with caution when AD is accompanied by retinal neurodegenerative diseases?
- Acellular Bowman Layer and Descemet Membrane Allografts for Non-Ectatic Anterior Corneal Diseases: A Narrative Review of Emerging Evidence
- Microcystic epithelial keratopathy associated with mirvetuximab soravtansine therapy: Multimodal corneal imaging and refractive changes
- Corneal epithelial regenerative medicine: lessons from somatic stem cell therapy toward iPS cell-based regeneration.
- Bone marrow kinase X-linked in pulmonary diseases: pathogenic gene, diagnostic biomarker, and treatment target—a narrative review
BibTeX
@article{bhujel2026gene,
title = {{Gene Therapy for Corneal Diseases.}},
author = {Basanta Bhujel and Kyu Sang Eah and Soon Suk Kang and Ho Seok Chung and Jae-Yong Kim},
journal = {Biotech (Basel (Switzerland))},
year = {2026},
month = sep,
doi = {10.3390/biotech15040080},
url = {https://europepmc.org/article/MED/42930058},
note = {CC BY},
}
RIS
TY - JOUR
TI - Gene Therapy for Corneal Diseases.
AU - Basanta Bhujel
AU - Kyu Sang Eah
AU - Soon Suk Kang
AU - Ho Seok Chung
AU - Jae-Yong Kim
PY - 2026
DA - 2026/09/22
JO - Biotech (Basel (Switzerland))
DO - 10.3390/biotech15040080
UR - https://europepmc.org/article/MED/42930058
AB - Corneal diseases are a major cause of blindness and visual impairment worldwide. Although conventional pharmacological therapies can alleviate mild to moderate corneal disorders, they often fail to restore vision in advanced disease, leaving corneal transplantation as the current standard treatment. However, donor tissue shortages, graft rejection, and surgical complications continue to limit its long-term success, highlighting the urgent need for effective nonsurgical therapeutic strategies. Gene therapy has emerged as a promising approach for treating inherited and acquired corneal diseases by targeting the underlying molecular mechanisms that drive disease progression. Recent advances in genome-editing technologies, gene-delivery systems, and vector engineering have substantially expanded the clinical potential of gene-based interventions. This review summarizes current progress in gene-editing strategies, gene-delivery platforms, and their therapeutic applications across a broad spectrum of corneal diseases. In addition, we discuss the major challenges and future perspectives associated with delivery efficiency, safety, vector optimization, and clinical translation. Collectively, these advances highlight the potential of gene therapy to transform the management of corneal diseases by providing safe, targeted, and long-lasting therapeutic strategies for restoring corneal function and vision.
SN - 2673-6284
ER -